about
Study Design of VESUTO®: Efficacy of Tiotropium/Olodaterol on Lung Hyperinflation, Exercise Capacity, and Physical Activity in Japanese Patients with Chronic Obstructive Pulmonary Disease.The pilot trial of the prevention of the increase in electrical taste thresholds by zinc containing fluid infusion during chemotherapy to treat primary lung cancer.Improvement of Airflow Limitation by Fluticasone Propionate/Salmeterol in Chronic Obstructive Pulmonary Disease: What is the Specific Marker?Effects of pharmacologic treatment based on airflow limitation and breathlessness on daily physical activity in patients with chronic obstructive pulmonary disease.Differences in physical activity according to mMRC grade in patients with COPDChylothorax Associated with Chronic Lymphocytic Leukemia.Cigarette smoke augments MUC5AC production via the TLR3-EGFR pathway in airway epithelial cells.TLR3 activation augments matrix metalloproteinase production through reactive nitrogen species generation in human lung fibroblasts.Inhibitory effects of theophylline on the peroxynitrite-augmented release of matrix metalloproteinases by lung fibroblasts.Oxidative stress enhances toll-like receptor 3 response to double-stranded RNA in airway epithelial cells.Angioimmunoblastic lymphadenopathy with dysproteinaemia accompanied by pleural effusion.Walking Pattern in COPD Patients.Oxidative stress augments toll-like receptor 8 mediated neutrophilic responses in healthy subjects.25-Hydroxycholesterol enhances cytokine release and Toll-like receptor 3 response in airway epithelial cells.Possible impact of salivary influence on cytokine analysis in exhaled breath condensate.The influence of free 3-nitrotyrosine and saliva on the quantitative analysis of protein-bound 3-nitrotyrosine in sputum.Severe gustatory disorder caused by cisplatin and etoposide.25-hydroxycholesterol promotes fibroblast-mediated tissue remodeling through NF-κB dependent pathway.Relationship between alveolar nitric oxide concentration in exhaled air and small airway function in COPD.Persistent elevation of exhaled nitric oxide and modification of corticosteroid therapy in asthma.Molecular mechanism of the additive effects of leukotriene modifier in asthmatic patients receiving steroid therapy.The regulation of amiloride-sensitive epithelial sodium channels by tumor necrosis factor-alpha in injured lungs and alveolar type II cells.Activation of Toll-like receptor 3 augments myofibroblast differentiation.Peroxynitrite augments fibroblast-mediated tissue remodeling via myofibroblast differentiation.Peak expiratory flow variability adjusted by forced expiratory volume in one second is a good index for airway responsiveness in asthmatics.Reduced level of physical activity in Japanese patients with chronic obstructive pulmonary disease.Cigarette smoke augments the expression and responses of toll-like receptor 3 in human macrophages.Improved quality of life in asthma patients under long-term therapy: Assessed by AHQ-Japan.Importance of assistance by caregivers for inhaled corticosteroid therapy in elderly patients with asthma.Changes in forced expiratory volume in 1 second over time in patients with controlled asthma at baseline.Progression of Irreversible Airflow Limitation in Asthma: Correlation with Severe Exacerbations.Validation of the triaxial accelerometer for the evaluation of physical activity in Japanese patients with COPD.Stratifying a risk for an increased variation of airway caliber among the clinically stable asthma.Ongoing allergic rhinitis impairs asthma control by enhancing the lower airway inflammation.Verification of a Motion Sensor for Evaluating Physical Activity in COPD Patients.Efficacy of tiotropium/olodaterol on lung volume, exercise capacity, and physical activity.Increased 25-hydroxycholesterol concentrations in the lungs of patients with chronic obstructive pulmonary diseasePrimary pulmonary melanoma diagnosed by semi-rigid thoracoscopy[A case of plasmacytoma of the ribs with intrathoracic tumors]Change in cytokeratin 19 fragment level according to the severity of pulmonary alveolar proteinosis
P50
Q33890852-4FCA1DCF-06D3-4526-8390-FBF9BD4819A2Q34309725-92722C8B-3B52-454F-B971-4C096901898CQ35119108-FB485475-A058-4D5B-9FD9-7B655837EC46Q35841545-351A6B66-1AED-456D-A7A0-145542922E33Q37265683-B7E8869B-A47E-4DB6-969F-AA5D6D990550Q37616842-2D7A048E-6523-4943-BD7A-6FAB6F900C0FQ38861065-FD609911-559B-46E9-B970-7DDB6637ED6EQ39001629-71EB5BB3-9089-495B-92F3-617E52172EA6Q39404591-E7239A9F-452D-4D58-9330-9C5E6EE077B3Q39825766-8ABEC6B3-BBC0-4FB8-B929-A444B055D612Q40515573-A97E2665-3989-4CD0-9F9D-4F13EAB3FCF4Q41218082-5C068725-6C18-4B89-91EF-9200B6BFF73DQ41813669-B20BC868-B223-4FFF-B46F-4373438E90D8Q41868351-0B22AB13-2AC1-49BE-956B-A759C7FEDA65Q42076954-C6541E11-A3D1-458C-839B-4AB98CBFE47CQ42076964-6F2AC5DA-3DE3-41E9-9501-A50B292D41B0Q43998068-281434D4-343F-4673-A291-AD08B3546DEFQ44039232-BB20A343-11E0-4DAB-9733-E84EBE04682EQ45907209-8E0159EF-2F47-4972-B0BE-8AA2AC22F13AQ46054617-FB7D981B-A9BF-4AD2-8CAD-4ACD212D07A5Q46157229-CD9A077A-A209-4308-918A-4DADA68A340DQ46159196-060F71E3-4B0A-4D8D-B48F-86D4A5ECB232Q46260943-ABAC332D-D2FC-4839-8975-C4E4A182D396Q46368275-0947A5BB-A46C-4DF6-9EBE-A36ABB8EFD6FQ46541314-22B1D447-36BB-4354-851C-DB355DB43773Q47611453-EE16E3BC-B3AB-4E5B-9529-E9A36C82F538Q47756462-2C1D84B8-B43E-442A-A191-DE3589624E94Q48023555-3E900FB9-51DB-44BA-95D1-90A1BC5DDEB8Q51119595-4BAE0379-5DC3-408E-8EEF-24BC60B7F630Q51247609-97A9E0C9-A11D-4C3C-A78A-691CBE787F9DQ51281820-D0E493CE-97A5-49CB-833C-1BC1FEB84805Q53095727-FA712D95-CC42-4D14-9853-15442B684EBFQ53123227-8D968C85-EC5E-4E8D-8BA5-93C5D0DEF65BQ54290383-3CFD81A5-49AE-4DD0-9A64-1116F320FFACQ55043726-D8371917-29B9-4AF2-8AB5-A7F0713CC795Q55053174-C18B79A4-EE94-48DF-9205-FB24C3DBAB11Q57998626-A3D6F1C4-E698-4674-8D5C-4E73D4C85647Q59137535-72F2EE61-B922-4C35-A1A0-A783AA08BC7CQ68197317-8B73244F-A6F2-4DD0-B6E6-0C4D23DE65C6Q77103359-4813B464-1F86-4C64-9296-FB35C4D98F7F
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Yoshiaki Minakata
@ast
Yoshiaki Minakata
@en
Yoshiaki Minakata
@es
Yoshiaki Minakata
@nl
Yoshiaki Minakata
@sl
type
label
Yoshiaki Minakata
@ast
Yoshiaki Minakata
@en
Yoshiaki Minakata
@es
Yoshiaki Minakata
@nl
Yoshiaki Minakata
@sl
prefLabel
Yoshiaki Minakata
@ast
Yoshiaki Minakata
@en
Yoshiaki Minakata
@es
Yoshiaki Minakata
@nl
Yoshiaki Minakata
@sl
P106
P31
P496
0000-0001-6993-0917